Stereotactic Ablative Radiotherapy May Be Feasible for Non-Small Cell Lung Cancer
the Cancer Therapy Advisor take:
Stereotactic ablative radiotherapy (SABR) could be an option for treating patients with operable stage I non-small cell lung cancer (NSCLC), a recent study published online first in the journal The Lancet Oncology has shown.
For the study, researchers conducted a pooled analysis of the STARS and ROSEL studies, which closed early due to slow accrual. In the intention-to-treat population, 58 patients with clinical T1-2a, N0M0, operable NSCLC were enrolled and randomly assigned 1:1 to SABR or lobectomy with mediastinal lymph node dissection or sampling.
Results showed that estimated overall survival at 3 years was 95% (95% CI: 85-100) in the SABR group versus 79% (95% CI: 64-97) in the lobectomy group (HR = 0.14; 95% CI: 0.017-1.190; log-rank P = 0.037). Researchers found that recurrence-free survival at 3 years was 86% (95% CI: 74-100) and 80% (95% CI: 65-97) in the SABR and surgery groups, respectively (HR = 0.69; 95% CI: 0.21-2.29; log-rank P = 0.54).
The researchers note that because of the small patient sample size and median follow-up of only 40.2 months in the SABR group and 35.4 months in the surgery group, additional randomized studies comparing the two in patients with operable NSCLC are needed.
Stereotactic ablative radiotherapy could be an option for treating patients with operable stage I NSCLC.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Resveratrol and Cancer
- Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis
- Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition
- ARID1A Mutations Might Predict Tumor Response to Immunotherapy
- Global Burden of Myeloma Increasing, Access to Treatments Lacking
- Longer Overall Survival with FOLFIRINOX Versus Gemcitabine/nab-Paclitaxel in Pancreatic Cancer
- Dendritic Cell Vaccine Plus Salvage Chemotherapy Active in Gastric Cancer
- Autophagy-Related Proteins May Be Prognostic Factors for CRC Survival With Chemotherapy
- Real-World Regorafenib Outcomes Mirror Clinical Trial Results in Metastatic Colorectal Cancer
- Identifying Potential Targets for Companion Diagnostic Tests Using Poly-Ligand Profiling